Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?

Gilead Sciences (GILD) shares have surged 27.2% over the past six months, significantly outperforming broader markets, primarily driven by the FDA approval of Yeztugo (lenacapavir), the first twice-yearly HIV PrEP, which strengthens its market-leading HIV franchise. Additionally, FDA approval for Livdelzi in liver disease and positive Phase III data for oncology drug Trodelvy further diversify its pipeline, notwithstanding some competitive headwinds in its oncology business. These strategic product advancements, alongside rising earnings estimates and a sustainable 2.83% dividend yield, reinforce GILD's growth prospects and financial stability, positioning it as a compelling investment despite some portfolio challenges.

Analysis

Gilead Sciences (GILD) has demonstrated significant market outperformance, with its stock gaining 27.2% over the past six months, contrasting sharply with its industry's 2.2% decline. This rally is primarily fueled by key regulatory approvals that strengthen its product pipeline and long-term growth outlook. The cornerstone of this positive momentum is the FDA's approval of Yeztugo (lenacapavir), the first twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP). This product offers a substantial competitive advantage over daily oral medications, addressing adherence challenges and positioning Gilead to capture new market segments while defending its HIV franchise against generic competition for Truvada and rivals like GSK. Further diversification is evident with the approval of Livdelzi (seladelpar) for primary biliary cholangitis, a move that validates the recent CymaBay acquisition and bolsters the liver disease portfolio. While the company's oncology segment faces challenges, including competitive pressure on its Cell Therapy franchise and lower-than-expected Q1 sales for Trodelvy, positive Phase III results for Trodelvy in first-line mTNBC suggest future growth potential. Financially, GILD trades at a 13.62x forward P/E, below the industry average, and benefits from upwardly revised earnings estimates for 2025 and 2026. A strong cash position of $7.9 billion supports a sustainable 2.83% dividend yield, though investors should note potential pressure on Biktarvy sales from the Medicare Part D redesign.

Key Decisions for Investors

• Investors should recognize the approval of the twice-yearly HIV PrEP, Yeztugo, as a major long-term growth driver that reinforces Gilead's market dominance and provides a new catalyst for revenue expansion.
• It is crucial to monitor the performance of the oncology franchise, specifically looking for stabilization in the Cell Therapy business and the successful commercialization of Trodelvy in new indications to offset current competitive headwinds.
• Given the stock's recent appreciation, the combination of a reasonable forward P/E ratio relative to peers and a sustainable 2.83% dividend yield presents a compelling case for both growth and income-oriented investors.
• Consider holding or initiating positions, while hedging for specific risks such as the impact of the Medicare Part D redesign on Biktarvy sales and ongoing competition in the oncology market.